Allarity Therapeutics, Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 26, 2026, Allarity Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, seven proposals were submitted to the Company’s stockholders of record for a vote. These proposals are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”). At the Annual Meeting, a total of 8,364,272 (or 54.10%) of the Company’s issued and outstanding shares of common stock held of record as of May 7, 2026, the record date for the Annual Meeting, were present either in person or by proxy, which constituted a quorum. The final voting results for each proposal are set forth below. For additional information regarding the proposals, please refer to the Proxy Statement. Proposal 1: The director nominee listed below was duly elected at the Annual Meeting for annual term expiring in 2029 was approved pursuant to the following votes: Nominee For Withheld Broker Non-Votes ─────────────────────────────────────────────────────── Jesper 3,748,814 187,812 4,427,646 Hoiland Proposal 2: The appointment of Wolf & Company, P.C. to serve as the Company’s independent registered public accounting firm for 2026 was ratified pursuant to the following votes: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────── 8,330,862 25,167 8,243 0 Proposal 3: The proposal to amend our Amended and Restated 2021 Equity Incentive Plan, to increase the aggregate number of shares of common stock authorized for grant from 1,521,990 to 2,021,990 was approved pursuant to the following votes: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────── 3,083,990 823,336 29,300 4,427,646 Proposal 4: The proposal for approval, on an advisory basis, of the compensation of the Company’s executive officers was approved pursuant to the following votes: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────── 3,621,297 301,684 13,645 4,427,646 Proposal 5: The proposal to approve the issuance of shares of our common stock pursuant to the Common Stock Purchase Agreement dated January 28, 2026 by and between the Company and Tumim Stone Capital LLC in excess of the Exchange Cap was approved pursuant to the following votes: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────── 3,168,301 722,610 45,715 4,427,646 Proposal 6: To approve an amendment to our Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law, did not pass, pursuant to the following votes: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────── 3,518,072 402,701 15,853 4,427,646 Proposal 7: The proposal to approve the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of the aforementioned proposals was approved pursuant to the following votes: For Against Abstentions Broker Non-Votes ──────────────────────────────────────────────────────────── 7,309,857 1,032,786 21,629 0

Item 8.01 Other Events. On June 30, 2026, the Company announced that the United States Patent and Trademark Office (USPTO) has granted the key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.